From earlier posts it seems clear that PRR has the global commercialization rights for CVac. That's the good news for CVac. But going back to my earlier question about patents and their scope, can anyone confirm whether PRR's patents mean that only PRR can commercialize drugs that target Mucin-1 ?
I strongly suspect not else why would Oncothyreon be developing Stimuvax (under license to Merck) which specifically targets MUC-1 (albeit that they are focusing on lung cancer at present instead of ovarian cancer).
I'm just wondering to what extent Oncothyreon/Merck may expect to compete with the likes of Prima and Dendreon. Who else is in this game ?
http://www.oncothyreon.com/clinical/stimuvax.html
- Forums
- ASX - By Stock
- IMM
- stimuvax phase iii (biomira, now oncothyreon)
stimuvax phase iii (biomira, now oncothyreon)
-
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
SBW
Shekel Brainweigh reports a 50% revenue increase in its Retail Innovation suite and delivers the first batch of 20 Smart Bays to Hitachi as part of a larger order
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
30.0¢ |
Change
-0.005(1.64%) |
Mkt cap ! $436.3M |
Open | High | Low | Value | Volume |
30.5¢ | 31.3¢ | 30.0¢ | $960.6K | 3.161M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
14 | 188729 | 30.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.0¢ | 46153 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
14 | 188729 | 0.300 |
12 | 236310 | 0.295 |
17 | 444259 | 0.290 |
8 | 1046339 | 0.285 |
9 | 253967 | 0.280 |
Price($) | Vol. | No. |
---|---|---|
0.310 | 46153 | 2 |
0.315 | 83754 | 5 |
0.320 | 172037 | 5 |
0.325 | 239547 | 4 |
0.330 | 68045 | 5 |
Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |